Join us today at 14.00 BST | 15.00 CET | 9.00 EST for an expert‑led webinar examining how smarter Phase 1-2 trial design can deliver deeper insights, support differentiation, and reduce late‑stage risk.
With Thomas Forst and Esteban Jodar Gimeno, the session will cover:
- When to involve patient populations earlier
- How to align endpoints to cardiometabolic comorbidities
- Integrating advanced biomarker and functional assessments
